The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
New Centre of Excellence at Electronic City campus to offer specialised care in epilepsy, cerebrovascular disorders, neurointervention, skull base and spine surgery
The newly established institute is equipped with advanced infrastructure designed to integrate multiple specialties under one roof
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
